NASDAQ:VIGL

Vigil Neuroscience (VIGL) Stock Forecast, Price & News

$9.36

+0.12 (+1.30%)

(As of 05/26/2023 08:48 PM ET)

Compare

Today's Range: $8.71
▼
$9.37
50-Day Range: $8.11
▼
$12.20
52-Week Range: $2.25
▼
$16.77

Volume: 23,700 shs
Average Volume: 22,552 shs
Market Capitalization: $334.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.80

Vigil Neuroscience MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 100.9% Upside
$18.80 Price Target
Short Interest: Bearish
3.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.22) to ($2.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

721st out of 1,012 stocks

Biological Products, Except Diagnostic Industry

113th out of 169 stocks

3.4

Analyst's Opinion

Consensus Rating
Vigil Neuroscience has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.80, Vigil Neuroscience has a forecasted upside of 100.9% from its current price of $9.36.
Amount of Analyst Coverage
Vigil Neuroscience has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
3.87% of the float of Vigil Neuroscience has been sold short.
Short Interest Ratio / Days to Cover
Vigil Neuroscience has a short interest ratio ("days to cover") of 22.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Vigil Neuroscience has recently increased by 4.37%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Vigil Neuroscience does not currently pay a dividend.
Dividend Growth
Vigil Neuroscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIGL.

2.7

News and Social Media Coverage

News Sentiment
Vigil Neuroscience has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Vigil Neuroscience this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
46.63% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.91% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vigil Neuroscience are expected to decrease in the coming year, from ($2.22) to ($2.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vigil Neuroscience is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vigil Neuroscience is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vigil Neuroscience has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vigil Neuroscience (NASDAQ:VIGL) Stock

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

VIGL Stock News Headlines

May 17, 2023 | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Earn FY2023 Earnings of ($2.14) Per Share

May 16, 2023 | americanbankingnews.com

Vigil Neuroscience, Inc. Forecasted to Earn FY2023 Earnings of ($1.85) Per Share (NASDAQ:VIGL)

May 29, 2023 | Stocks To Trade (Ad)

3 Free Stock Picks per Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 13, 2023 | americanbankingnews.com

Vigil Neuroscience, Inc. Expected to Post Q1 2024 Earnings of ($0.51) Per Share (NASDAQ:VIGL)

May 12, 2023 | msn.com

Vigil Neuroscience: Q1 Earnings Insights

May 11, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Vigil Neuroscience Inc (VIGL)

May 10, 2023 | finanznachrichten.de

Vigil Neuroscience, Inc.: Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023 | finance.yahoo.com

Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update

May 29, 2023 | Stocks To Trade (Ad)

3 Free Stock Picks per Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 9, 2023 | finance.yahoo.com

Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors

May 8, 2023 | finance.yahoo.com

Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

May 8, 2023 | finance.yahoo.com

Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans

April 15, 2023 | americanbankingnews.com

Comparing Revolution Medicines (NASDAQ:RVMD) & Vigil Neuroscience (NASDAQ:VIGL)

April 6, 2023 | americanbankingnews.com

ERYTECH Pharma (NASDAQ:ERYP) vs. Vigil Neuroscience (NASDAQ:VIGL) Financial Review

April 5, 2023 | americanbankingnews.com

Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by Wedbush

April 3, 2023 | benzinga.com

What 4 Analyst Ratings Have To Say About Vigil Neuroscience

March 31, 2023 | msn.com

Mizuho Initiates Coverage of Vigil Neuroscience (VIGL) with Buy Recommendation

March 31, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH), Alcon (ALC) and Vigil Neuroscience Inc (VIGL)

March 31, 2023 | americanbankingnews.com

Vigil Neuroscience (NASDAQ:VIGL) Coverage Initiated by Analysts at Mizuho

March 30, 2023 | markets.businessinsider.com

Vigil Neuroscience Inc (VIGL) Receives a New Rating from Mizuho Securities

March 30, 2023 | seekingalpha.com

Vigil surges after FDA lifts partial hold on neurological disorder drug VGL101

March 30, 2023 | finance.yahoo.com

Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101

March 29, 2023 | americanbankingnews.com

Vigil Neuroscience (NASDAQ:VIGL) PT Raised to $13.00 at Morgan Stanley

March 28, 2023 | americanbankingnews.com

Comparing Vaxart (NASDAQ:VXRT) and Vigil Neuroscience (NASDAQ:VIGL)

March 26, 2023 | americanbankingnews.com

Vigil Neuroscience, Inc. to Post Q1 2023 Earnings of ($0.45) Per Share, HC Wainwright Forecasts (NASDAQ:VIGL)

March 23, 2023 | benzinga.com

Vigil Neuroscience Stock (NASDAQ:VIGL), Dividends

March 23, 2023 | americanbankingnews.com

Vigil Neuroscience, Inc. Expected to Earn Q1 2023 Earnings of ($0.49) Per Share (NASDAQ:VIGL)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

VIGL Company Calendar

Last Earnings: 3/21/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VIGL
CUSIP: N/A
CIK: 1827087
Web: vigilneuro.com
Phone: 857-254-4445
Fax: N/A
Employees: 2,021
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.80
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +100.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,310,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.60%
Return on Assets: -37.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.30
Quick Ratio: 23.30

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.80 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 35,690,000
Free Float: 19,045,000
Market Cap: $334.06 million
Optionable: Not Optionable
Beta: 3.33

Key Executives

Dr. Ivana Magovcevic-Liebisch J.D. (Age 56)
Ph.D., Pres, CEO & Director
Comp: $713.25k

Ms. Jennifer Ziolkowski CPA (Age 49)
CPA, Chief Financial Officer
Comp: $518.04k

Dr. Spyridon Papapetropoulos M.D. (Age 50)
Ph.D., Chief Medical Officer
Comp: $601.74k

Park Guo CPA
Accounting Mang.

Kelly Neelon Ph.D.
VP of CMC & Technical Operations

Ms. Sarah Carmody
VP of Investor Relations & Corp. Communications

Mr. Christopher Verni J.D. (Age 48)
Gen. Counsel

April Effort M.B.A.
M.S., Head of Corp. Devel.

Mr. Evan A. Thackaberry DABT (Age 50)
Ph.D., Sr. VP & Head of Early Devel.

Mr. Charles Maggs
Head of FP&A

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIGL Stock - Frequently Asked Questions

Should I buy or sell Vigil Neuroscience stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIGL shares.
View VIGL analyst ratings or view top-rated stocks.
What is Vigil Neuroscience's stock price forecast for 2023?: 5 equities research analysts have issued 1-year target prices for Vigil Neuroscience's shares. Their VIGL share price forecasts range from $13.00 to $24.00. On average, they expect the company's share price to reach $18.80 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts.
How have VIGL shares performed in 2023?: Vigil Neuroscience's stock was trading at $12.50 at the start of the year. Since then, VIGL stock has decreased by 25.1% and is now trading at $9.36.
View the best growth stocks for 2023 here.
When is Vigil Neuroscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VIGL earnings forecast.
How were Vigil Neuroscience's earnings last quarter?: Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its earnings results on Tuesday, March, 21st. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.14.
When did Vigil Neuroscience IPO?: (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

What is Vigil Neuroscience's stock symbol?: Vigil Neuroscience trades on the NASDAQ under the ticker symbol "VIGL."
Who are Vigil Neuroscience's major shareholders?: Vigil Neuroscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.32%), Barclays PLC (0.29%), Citigroup Inc. (0.26%), Susquehanna International Group LLP (0.16%), Jane Street Group LLC (0.08%) and Bank of America Corp DE (0.05%). Insiders that own company stock include Christopher Verni, Clay Thorp, Evan Thackaberry, Ivana Magovcevic-Liebisch and Spyros Papapetropoulos.
View institutional ownership trends.
How do I buy shares of Vigil Neuroscience?: Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vigil Neuroscience's stock price today?: One share of VIGL stock can currently be purchased for approximately $9.36.
How much money does Vigil Neuroscience make?: Vigil Neuroscience (NASDAQ:VIGL) has a market capitalization of $334.06 million. The company earns $-68,310,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.
How many employees does Vigil Neuroscience have?: The company employs 2,021 workers across the globe.
How can I contact Vigil Neuroscience?: The official website for the company is vigilneuro.com. The company can be reached via phone at 857-254-4445 or via email at scarmody@vigilneuro.com.

This page (NASDAQ:VIGL) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial